SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 175.32+4.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: wpckr who wrote (652)5/15/1998 7:28:00 AM
From: Harold Engstrom  Read Replies (1) of 1686
 
Biogen relies on Avonex, a recombinant beta interferon, for most of its revenues. Schering and Ares-Serono also make beta interferon. Serono is unlikely to get approval in the US because Avonex is protected under the orphan drug act, but they can now officially sell in Europe. However, both Schering and A-S's interferons are injected sub-cutaneously every other day(v. once per week), cause a much larger percentage (20% v. less than 5%) of patients to develop anti-bodies, and have not been shown to be as statistically effective as Avonex.

In Europe, A-S will be a serious competitor. Biogen's European marketing effectiveness is unknown as of yet.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News